期刊文献+

HPLC法测定氯诺昔康片中有关物质的含量 被引量:1

Content Determination of the Related Substances in Lornoxicam Tablets by HPLC
原文传递
导出
摘要 目的:建立测定氯诺昔康片有关物质含量的方法。方法:采用高效液相色谱法。色谱柱为Thermo Hypersil ODS,流动相A为1%醋酸铵溶液-10%氢氧化四丁基铵溶液-甲醇(1 000∶6.4∶4.4),流动相B为乙腈-辛胺(99.9∶0.1),梯度洗脱,流速为0.5ml/min,可变波长检测器,检测波长为280 nm,柱温为35℃。测定3批样品中4种已知杂质2-氨基吡啶、HN-40244、HN-10004、HN-10002及其他单个杂质和总杂质含量。结果:4种已知杂质以及其他单个杂质均能与氯诺昔康完全分离,4种已知杂质在各自的检测质量浓度范围内线性关系良好(r≥0.999 8),检测限分别为0.64、0.28、0.29、0.24 ng,定量限分别为1.30、0.93、0.95、0.40ng。结论:建立的方法结果准确,可全面检测氯诺昔康片中有关物质的含量。 OBJECTIVE: To establish a method for the content determination of the related substances in Lomoxicam tablets. METHODS: HPLC method was adopted. The determination was performed on Thermo Hypersil ODS column with 1% ammonium acetate solution-10% tetrabutyla mmonium hydroxide solution-methanol (1 000:6.4:4.4) as the mobile phase A and acetonitrile-oc- tylamine (99.9:0.1) as mobile phase B (gradient elution). The flow rate was 0.5 ml/min and the column temperature was 35 ~2. The detection wavelength of VWD detector was set at 280 nm. The contents of 4 kinds of known impurity (2-amino pyridine, HN- 40244, HN-10004 and HN-10002), other single impurity and total impurity were all determined in 3 batches of samples. RESULTS: 4 kinds of known impurities and other single impurity were all separated from lornoxicam completely. There was a good linear rela- tionship between calibration curve and the concentration of 4 kinds of known impurities (r〉0.999 8). The limits of detection were 0.64,0.28, 0.29 and 0.24 ng, respectively. The limits of quantification were 1.30 ng, 0.93 ng, 0.95 ng and 0.40 ng, respectively. CONCLUSIONS: The method is accurate and suitable for the content determination of the related substances in Lomoxicam tablets.
出处 《中国药房》 CAS CSCD 2013年第37期3537-3540,共4页 China Pharmacy
关键词 氯诺昔康片 高效液相色谱法 有关物质 Lornoxicam tablets HPLC Related substances
  • 相关文献

参考文献6

二级参考文献13

  • 1邵长周,瞿介明,何礼贤.第3代口服头孢菌素——头孢泊肟酯[J].中国新药与临床杂志,2004,23(11):746-750. 被引量:12
  • 2Radhofer WS, Dittrich P. Determination of the novel nonsteroidal antiinflammatory drug lomoxicam and its main metabolite in plasma and synovial fluid. J Chromatogr B, 1998,707 ( 1 - 2 ) : 151.
  • 3CHENZhong—wamg(陈忠望).Two kinds 0f selective COX—2 inkbitors(两种新的选择性环氧合酶抑制剂)[J].Foreign Med Sci Pharm(国外医学一药学分册),1997,24(3):168-168.
  • 4Julia A Balfour, Andrew Fitton, Lee B BarradeIl. Lomoxicam, a review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.Drugs, 1996,51 (4) :639.
  • 5[1]Suwa T, Urano H, Shinohara Y. Simultaneous high performance liquid chromatographic determination of lomoxicam and its 5'-hydroxy metabolite in human plasma using eleetrochemical deteetion[J]. J Chromatogr, 1993,617:1105.
  • 6[2]Radhofer WS, Dittrich P. Determination of the novel nonsteroidal anti-inflammatory drug lomoxicam and its main metabolite in plasma and synovial fluid[J]. J Chromatogr B Biomed Sci Appl,1998,707:1.
  • 7[1]Staunstrup H, Ovesen J, Larsen UT, et al. Efficacy and tolerability of lornoxicam versus tramadol in postoperative pain [J]. J Clin Pharmacol, 1999, 39 (8): 834-841.
  • 8[2]Charles JJ, Bertucat M. Simultaneous high performance liquid chromatographic analysis of non-steroidal anti-inflammatory oxicams in pharmaceutical preparations [J]. JLiq Chromatogr Relat Technol, 1999, 22 (13): 2009-2021.
  • 9Yamasaki T,Moritake K,Akiyama Y,et al.Microvascular Doppler ultrasound-assisted neuroendoscopic surgery [J].Br J Neurosurg,2000,14 (5): 464-467.
  • 10Auer LM.Ultrasound stereotaxic endoscopy in neurosurgery[J].Acta Neurochir Suppl,1992,54: 34-41.

共引文献8

同被引文献9

  • 1Massaro AM,Lenz KL.Aprepitant:a novel antiemetic for chemotherapy-induced nausea and vomiting[J].Ann Pharmacother,2005,39(1):77.
  • 2Grunberg SM,Deuson RR,Mavros P,et al.Incidence of chemotherapy-induced nausea and emesis after modern antiemetics[J].Cancer,2004,100(10):2 261.
  • 3Meenakshi G,Deepika T.Aprepitant:a novel drug to prevent cancer chemotherapy induced nausea and vomiting[J].JK Science,2010,12(1):46.
  • 4U.S.Food and Drug Administration.Aprepitant[EB/OL].(2003-03-27)[2013-09-28].http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm.
  • 5国家食品药品监督管理总局.阿瑞匹坦胶囊(进口药品)[EB/OL].(2013-09-22)[2013-11-20].http://www.sfda.gov.cn/WS01/CL0001/.
  • 6Benjamin T,Rajyalakshmi CH,Rambabu C.Stress degradation studies and validation method for quantification of aprepitent in formulations by using RP-HPLC[J].International Journal of ChemTech Research,2013,5(4):1 462.
  • 7Skrdla PJ,Abrahim A,Wu Y.An HPLC chromatographic reactor approach for investigating the hydrolytic stability of a pharmaceutical compound[J].J Pharma Biomed Anal,2006,41(3):883.
  • 8Nama S,Chandu BR,Awen BZ.Development and valida tion of a new RP-HPLC method for the determination of aprepitant in solid dosage forms[J].Tropical Journal of Pharmaceutical Research,2011,10(4):491.
  • 9《化学药物杂质研究的技术指导原则》课题研究组.化学药物杂质研究的技术指导原则[EB/OL].(2007-08-23)[2013-12-07].http://www.cde.org.cn/zdyz.do?method=initValue&frameStr=0.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部